pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
392
stories
6d
5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry
stat
6d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
6d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
7d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
7d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
7d
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
stat
7d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
7d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
7d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
7d
BMS R&D head to depart amid restructure
biospace
7d
Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1
endpoints
7d
BMS reunites R&D divisions under Cristian Massacesi, while Robert Plenge departs
fiercebiotech
7d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
8d
Drug price hikes in Germany could push US costs higher, study says
biopharma dive
8d
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
fiercebiotech
9d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
10d
Ramaswamy’s biotech baggage haunted his political run
biopharma dive
10d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
12d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
13d
‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
fiercebiotech
13d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
13d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
13d
Novo, Pfizer make CFO hires; Alnylam's chief commercial officer exits as struggles continue
endpoints
14d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
14d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
15d
Biopharma likely to climb higher after ‘blue wave,’ analysts say
biopharma dive
15d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
15d
Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
biospace
15d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
← prev
page 2 of 14
next →